<DOC>
	<DOC>NCT00917150</DOC>
	<brief_summary>To investigate the efficacy and safety of OPC-6535 in COPD patients, using the measurement of trough FEV1 over time as the primary endpoint.</brief_summary>
	<brief_title>To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Age 40 to 75 years, inclusive, at the time informed consent is obtained Ability to provide own written informed consent Agree to use an appropriate method of contraception until 3 months after the last dose of the investigational medicinal product (IMP) A rating of 1 or higher on the Goddard scale in assessment of emphysema severity by chest CT scan at screening Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) of less than 70% at screening Cigarette smoking history of at least 20 pack years at screening Subjects with obstructive disorders due to bronchial asthma Subjects receiving longterm oxygen therapy Subjects with active tuberculosis or obvious bronchiectasis Complication of malignant tumor Uncontrolled cardiovascular, endocrine, blood, or nervous system disorders Uncontrolled condition with COPD exacerbation of level 2 or 3 within 8 weeks prior to the start of washout period (within 12 weeks prior to start of treatment period)</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>emphysema</keyword>
</DOC>